SAN DIEGO & VIENNA--(BUSINESS WIRE)--Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced positive results from a phase I multiple dose safety and pharmacokinetic study of its lead product, once-weekly inhaled AIR645 in healthy adults and mild asthmatics. The results were presented today by Dr. Michael Hodges, M.D., Chief Medical Officer for Altair Therapeutics at the European Respiratory Society Annual Congress in Vienna.
